BioSolution Designs and RoosterBio Announce Collaboration on Genetically Modified MSCs for Biotherapeutic Development
Retrieved on:
Thursday, May 2, 2024
FREDERICK, Md., May 2, 2024 /PRNewswire-PRWeb/ -- BioSolution Designs (BSD), a biotechnology invention studio developing proprietary platforms for multigenic gene and cell therapies, today announced its ongoing strategic collaboration with RoosterBio, a leading provider of human mesenchymal stem/stromal cells (MSCs), highly engineered media solutions, and bioprocess development services.
Key Points:
- Together, BSD and RoosterBio deliver an end-to-end solution for the engineering and development of cell- and exosome-based therapeutics.
- FREDERICK, Md., May 2, 2024 /PRNewswire-PRWeb/ -- BioSolution Designs (BSD), a biotechnology invention studio developing proprietary platforms for multigenic gene and cell therapies, today announced its ongoing strategic collaboration with RoosterBio, a leading provider of human mesenchymal stem/stromal cells (MSCs), highly engineered media solutions, and bioprocess development services.
- "By combining Biosolution Designs' innovative multigenic technologies with our well-established cell therapy products and scalable bioprocess manufacturing platforms, we will accelerate the clinical progression of the next generation of cell and exosome therapeutics."
- "BSD is at the leading edge of advanced therapy engineering," said Tim Kelly, CEO of RoosterBio.